Advances in Angiostatic Treatment for Retinal Disease: Demystifying Novel Therapeutic Targets - a podcast by ReachMD

CME credits: 0.50

Valid until: 30-04-2022

Claim your CME credit at https://reachmd.com/programs/cme/advances-angiostatic-treatment-retinal-disease-demystifying-novel-therapeutic-targets/12490/

Current challenges in the treatment of neovascular retinal disease include the tremendous burden of treatment and suboptimal response to treatment in many cases. Strides have been made recently toward therapies that deliver increased efficacy vs traditional first-line therapies, a decreased treatment burden, or both. To achieve these ends, next-generation treatment strategies target multiple angiogenic cellular pathways at once. In this activity, experts in retinal disease treatment use custom animations to discuss the mechanisms of action of various novel treatment strategies. The latest clinical trial data for faricimab and OPT-302, two molecules currently in phase 3 clinical trials for the treatment of retinal disease, are also presented.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD